ClinicalTrials.gg
Active, not recruitingNCT06383390Updated Oct 8, 2026

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

A Phase 3 interventional study of Retatrutide and Placebo in Atherosclerotic Cardiovascular Disease (ASCVD) and Chronic Kidney Disease (CKD), sponsored by Eli Lilly and Company. Active, not recruiting at 742 sites in 27 countries. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
10,000
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Atherosclerosis by Eli Lilly and Company — 5 open to participants now, 7 under way, 4 of them phase 3. Atherosclerosis · Eli Lilly and Company.

Started
2024
with 2 others
Phase 3
4 of 10
2 open now
Registered
6th of 10
by date

Among the 10 studies in Atherosclerosis by Eli Lilly and Company, this one is one of 3 that started in 2024, is one of 4 in phase 3, and was the 6th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

5 of the 10 studies in Atherosclerosis by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Atherosclerosis by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.

03

Conditions studied

  • Atherosclerotic Cardiovascular Disease (ASCVD)
  • Chronic Kidney Disease (CKD)

Keywords

  • Cardiovascular Disease
  • Kidney Disease
  • Major Adverse Cardiovascular Events (MACE)
  • Renal Outcomes
  • Cardiovascular Risk Reduction
  • Kidney Disease Progression
  • Cardiometabolic Risk Factors
  • Cardiovascular Outcomes
  • Kidney Outcomes
  • Type 2 Diabetes
  • Heart Disease
  • Coronary Artery Disease
  • Cerebrovascular Disease
  • Peripheral Arterial Disease
  • Nonfatal Myocardial Infarction (MI)
  • Nonfatal Stroke
  • Cardiovascular (CV) Death
  • Hospitalization or Urgent Visit Due to Heart Failure (HF)
  • Renal Death
  • End Stage Kidney Disease (ESKD)
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants may be without type 2 diabetes (T2D), or with T2D if their (HbA1c) is 10% or lower
  • Participants have established atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD), as evidenced at least one of the following:

    • Coronary artery disease
    • Cerebrovascular disease
    • Peripheral arterial disease
    • Chronic kidney disease defined as:

      • \<45 millilitres/minute/1.73 meter squared (mL/min/1.73m\^2) and UACR >30 milligram/gram (mg/g) (0.030 mg/mg)
      • eGFR \<60 mL/min/1.73 m\^2 and UACR >100 mg/g (0.100 mg/mg), or
      • eGFR \<75 mL/min/1.73 m\^2 and UACR >300 mg/g (0.300 mg/mg) (eGFR is calculated by central lab based on Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine-cystatin c equation as determined by central lab)
  • A of ≥27.0 kilograms per meter squared (kg/m\^2)

Exclusion criteria

Exclusion Criteria:

Diabetes related:

  • Participants have Type 1 Diabetes or any history of diabetic ketoacidosis

CV related:

  • Participants have any of the following cardiovascular conditions ≤ 90 days prior to randomization:

    • Myocardial infarction
    • Acute coronary syndrome
    • Stroke, or
    • Coronary, peripheral, or carotid artery arterial revascularization procedure.
  • Have acute decompensated heart failure requiring hospitalization.
  • Have (NYHA) Classification Class IV heart failure at screening

Kidney related:

  • Participants have an \<20 mL/min/1.73 m\^2 at screening
  • Have UACR >5000 mg/g (5.000 mg/mg) at screening
  • Have received any form of dialysis ≤ 90 days from the date of randomization
  • Have either undergone a kidney transplant or have a transplant procedure scheduled

Other medical conditions:

  • Participants have had or plan to have a surgical treatment for obesity,
  • Have a history of chronic or acute pancreatitis
  • Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome type 2
  • Have a known gastric emptying abnormality, such as severe gastroparesis or gastric outlet obstruction
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
10,000 participants (estimated)

Study arms

  • Experimental
    Retatrutide

    Participants will receive escalated doses of retatrutide administered subcutaneously (SC) up to a maximum tolerated dose.

    Drug: Retatrutide

  • Placebo comparator
    Placebo

    Participants will receive matching placebo administered SC.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY3437943

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Time to First Occurrence of Composite Endpoints

    A composite endpoint includes nonfatal myocardial infarction (MI), nonfatal stroke, cardiovascular (CV) death, or hospitalization or urgent visit due to heart failure (HF).

    Time frame: Randomization up to Study Completion (Approximate 248 Weeks)

  2. Time to First Occurrence of Composite Endpoint of End Stage Kidney Disease (ESKD), ≥ 40% Sustained Decline in Estimated Glomerular Filtration Rate (eGFR), CV Death or Renal Death

    ESKD is defined as the following individual components: persistent eGFR \<15 mL/min/1.73 m\^2 confirmed by 2 measurements at least 4 weeks apart at the central laboratory, initiation of dialysis for at least 28 days, receiving a kidney transplant. Sustained decline in eGFR (≥40%) will be confirmed by a repeated measure at least 4 weeks after the first result.

    Time frame: Randomization up to Study Completion (Approximate 248 Weeks)

Secondary outcomes

  1. Time to First Occurrence of Composite Endpoint of Major Cardiovascular Events (MACE-3)

    MACE-3 includes CV death, nonfatal MI, and nonfatal stroke.

    Time frame: Randomization up to Study Completion (Approximate 248 Weeks)

  2. Time to First Occurrence of Composite Endpoint of CV death, or hospitalization or urgent visit due to HF

    Time to First Occurrence of Composite Endpoint of CV death, or hospitalization or urgent visit due to HF.

    Time frame: Randomization up to Study Completion (Approximate 248 Weeks)

  3. Time to Occurrence of All-Cause Death

    Time to all-cause death.

    Time frame: Randomization up to Study Completion (Approximate 248 Weeks)

  4. Time to First Occurrence of composite endpoint of ≥ 40% Sustained Decline in eGFR, End-Stage Renal Disease (ESRD), or Renal Death

    Time frame: Randomization up to Study Completion (Approximate 248 Weeks)

  5. Percentage change from Baseline in Albuminuria urinary albumin/creatinine ratio (UACR) in Participants with UACR ≥30 mg/g (0.03 mg/mg) at baseline

    Time frame: Randomization up to Study Completion (Approximate 248 Weeks)

07

Study locations

742 sites

Showing the first 100 of 742 sites across 27 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Heerspink HJL, van Raalte DH, Bjornstad P, Bunck MC, Wu P, Tunali I, Milicevic Z, Koeneman L. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease. Nephrol Dial Transplant. 2026 May 29;41(6):1058-1068. doi: 10.1093/ndt/gfaf230. PubMed 41160422 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Feb 2029, 58 months after the start.

Of 36 industry-sponsored phase 3 interventional studies under Atherosclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's planned 58 months is above that.

Counting every sponsor, half of 53 studies reached it within 35 months; a quarter within 21 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2024
First posted
Apr 25, 2024
StartActual
Apr 30, 2024
Primary completionEst.
Feb 2029
CompletionEst.
Feb 2029
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06383390
Responsible party
Sponsor
First posted
Apr 25, 2024
Start date
Apr 30, 2024
Primary completion
Feb 2029 (estimated)
Completion
Feb 2029 (estimated)
Last update
Oct 8, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Retatrutide

Start the discussion